News & Views

Telix today announces thirteen abstract presentations featuring the Company’s ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Hamburg from 19 – 23 October 2024. 

Telix today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of 68Ga-PSMA-11[1] injection) to select patients for PSMA[2]-targeted radionuclide therapy.

Telix today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA[1]-targeted radionuclide therapy.

Telix today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix’s first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentuximab) in recurrent clear cell renal cell carcinoma (ccRCC) after surgery.

During Prostate Cancer Awareness, Telix is speaking with the physicians, advocates and patients on the front line of fighting prostate cancer. Our third interview in the series is with Mike Crosby CDR ret., a Veteran, prostate cancer survivor and patient advocate. We spoke to him about his personal battle and how he is fighting for better outcomes for Veterans with the disease.

Telix and RLS (USA) Inc., America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent company, RLS Group Ltd. The acquisition significantly expands Telix’s North American manufacturing footprint and establishes the basis of a next generation radiometal production network to benefit Telix and select strategic commercial partners. 

Telix today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET agent, Zircaix® (TLX250-CDx) for the imaging of kidney cancer in the United States (U.S.), subject to regulatory approval.

During Prostate Cancer Awareness, Telix is speaking with the physicians, advocates and patients on the frontlines of fighting prostate cancer.

Telix today announces that primary results from its Phase III ZIRCON trial have been published in The Lancet Oncology, reporting that Telix’s first-in-class investigational PET agent, TLX250-CDx (Zircaix®, 89Zr-girentuximab), is highly accurate in detecting and characterising clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs).

During Prostate Cancer Awareness, Telix is speaking with the physicians, advocates and patients on the frontlines of fighting prostate cancer.